Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hair serum shows promise in battle against balding

NCT ID NCT06556056

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study tested a new hair growth serum called SesZen-Bio against a standard treatment (minoxidil 1%) and a placebo in 108 adults with mild to moderate androgenic alopecia (male or female pattern baldness). Participants applied the serum daily to their scalp for several weeks. Researchers measured changes in hair thickness, density, and growth rate using a special imaging device. The goal was to see if the new serum is safe and effective for treating hair loss.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SesZen-Bio Serum (topical) and Minoxidil 1% serum (topical)
What this could lead to
If it works, this could offer a new topical option for people with mild to moderate hair loss, potentially with fewer side effects than standard treatments.
What could go wrong
This is a small, early-stage study (108 people) with no phase designation. Results may not apply to everyone, and the new serum may not outperform existing options like minoxidil.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

108 people

The number who actually took part.

Started

Jun 2024

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age: 25 to 45 years and above (both inclusive) at the time of consent. 2. Sex: Males and non-pregnant/non-lactating females (preferably equal number of males and females). 3. Females of childbearing potential must have a self-reported negative urine pregnancy. 4. Subject is in good general health as determined by the Investigator on the basis of medical history. 5. Patients having mild to moderate androgenic alopecia (Grade I to III) during clinical study and grade will be evaluated by the dermatologist by using Norwood-Hamilton classification and Ludwig pattern scale for female. 6. Female with 40-50 counts and male with 25 -30 counts of hair fall at screening. 7. Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study. 8. If the subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation. 9. Patients are willing to give written informed consent and are willing to follow the study procedure. 10. Patients who commit not to use any other medicated/ prescription shampoos/hair care products (containing Minoxidil), any other hair growth products or hair colour or dye, other than the test products for the entire duration of the study. 11. Willing to use test products throughout the study period. 12. Subject is willing and able to follow and allow study staff to performed study test methods. 13. Subject is willing and able to follow the study directions, to participate in the study, returning for all specified visits. 14. Subject must be able to understand and provide written informed consent to participate in the study. Exclusion Criteria: 1. Subject have history of severe hair fall due to any clinically significant problems like anaemia, thyroid problems. 2. Subject have history of any dermatological condition of the scalp other than hair loss and dandruff. 3. Subject have history of any prior hair growth procedures (e.g. hair transplant or laser). 4. Subject who had taken topical treatment of hair loss for at least 4 weeks. 5. Subject who had taken any systemic treatment for at least 3 months. 6. History of alcohol or drug addiction. 7. Subject having history or resent condition of irritated or visibly inflamed scalp or severe scalp disease. 8. Subject having history or present condition of an allergic response to any cosmetic products, any other condition which could warrant exclusion from the study. 9. Pregnant or breast feeding or planning to become pregnant during the study period. 10. History of chronic illness which may influence the cutaneous state. 11. Subject have participated any clinical research study related to hair care products. 12. Subject have history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Androgenic alopecia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • NovoBliss Research Private Limited

    Ahmedabad, Gujarat, 382481, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.